Lupin rose 6.35% to Rs 1,757.05 at 14:46 IST on BSE after consolidated net profit fell 11.92% to Rs 529.75 crore on 11.04% increase in total income to Rs 3621.14 crore in Q3 December 2015 over Q3 December 2014.
The result was announced during trading hours today, 5 February 2016.Meanwhile, the BSE Sensex was up 254.75 points, or 1.05%, to 24,593.18.
On BSE, so far 2.60 lakh shares were traded in the counter, compared with an average volume of 56,843 shares in the past one quarter. The stock hit a high of Rs 1,764 and a low of Rs 1,603.20 so far during the day. The stock hit a record high of Rs 2,127 on 6 October 2015. The stock hit a 52-week low of Rs 1,540 on 10 February 2015. The stock had underperformed the market over the past one month till 4 February 2016, sliding 8.10% compared with 5.01% decline in the Sensex. The scrip had also underperformed the market in past one quarter, falling 11.15% as against Sensex's 8.34% fall.
The large-cap company has an equity capital of Rs 90.11 crore. Face value per share is Rs 2.
Lupin is a pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Powered by Capital Market - Live News